一分钟看懂
这是一项关于前列腺癌的I 期 / II 期研究，登记的药物或干预包括AZD0516；AZD9574，当前状态为招募中。登记地点显示中国长沙、成都、武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
AZD0516；AZD9574 · I 期 / II 期
登记条件中文摘要
登记的基本范围为男性，年龄18 岁至130 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 长沙
- Research Site · 成都
- Research Site · 武汉
公开的入选条件
- * Histologically or cytologically confirmed diagnosis of metastatic adenocarcinoma of the prostate. Focal high grade neuroendocrine features are permitted.
- * Measurable PSA ≥ 1 μg/L (≥ 1 ng/mL).
- * Surgically or medically castrated with serum testosterone levels ≤ 50 ng/dL (≤ 1.75 nmol/L) within ≤ 28 days before treatment allocation. Ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) modulator for participants who h
- * Eastern cooperative oncology group (ECOG) performance status of 0 or 1.
- * Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention).
- * Provision of baseline archival or newly obtained formalin-fixed paraffin-embedded (FFPE) tumour sample is mandatory.
- * Documented current evidence of metastatic prostate cancer
- * Life expectancy of at least 12 weeks in the opinion of the investigator
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07181161；登记信息更新于 2026-09-25。